Biomarkers Market

Biomarkers Market by Product & Service (Consumable, Service, Software), Type (Safety, Efficacy, Validation), Disease (Cancer, Infectious, Neurological), Application (Diagnostics, Drug Discovery, Personalized Medicine), Region - Global Forecast to 2028

Report Code: BT 2120 Feb, 2023, by marketsandmarkets.com

The global biomarkers market in terms of revenue was estimated to be worth $59.1 billion in 2023 and is poised to reach $104.0 billion in 2028, growing at a CAGR of 12.0% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Factors responsible for the growth in the global market are mainly factors such as the growing importance of companion diagnostics, the increasing prevalence of cancer and cardiac problems, increasing funds and grants for biomarker research, continuous product innovations, and biomarker advancements.

Biomarkers Market Trends

Biomarkers Market

To know about the assumptions considered for the study, Request for Free Sample Report

Biomarkers Market Dynamics

Driver: Increasing prevalence of cancer worldwide

The future burden of cancer is expected to be even larger due to the increasing prevalence of smoking, unhealthy food habits, and physical inactivity, among others. Biomarkers can indicate a variety of health or disease characteristics. Cancer is a complex disease developed through a multi-stage carcinogenesis process involving multiple molecular pathway events creating a hurdle in diagnosis, prognosis, and therapy. Due to the complex nature of cancer, a single marker is not helpful. Moreover, each type of cancer differs from others in molecular profile. The discovery of new biomarkers provides new opportunities for deriving therapeutic strategies designed to reverse dysregulation in cancer. Thus, the increasing prevalence of cancer will drive biomarker research and, in turn, the growth of the global market.

Restraint: High capital investments and lengthy timelines for biomarker development

Huge capital investments are required for the discovery, development, and validation of biomarkers. This weighs down the growth of the global market and other related markets such as diagnostics (in vitro diagnostics or companion diagnostics) and personalized medicines. The discovery of candidate biomarkers far outpaces the current ability to validate them. This is a major challenge faced by the personalized medicines market. Also, due to the high drug attrition rate in clinical trials (with almost 30% of drugs failing in phase III), diagnostics manufacturers face enormous financial challenges. To pass an IVD from the regulators, manufacturers need successful phase III clinical trials, which are in turn dependent on well-validated biomarker tests. Huge investments are required to run clinical trials and address stringent regulatory requirements, which not only affect the ability of small companies to develop biomarkers but also severely affect innovation. Hence, along with high capital investments, the low cost-benefit ratio also hinders the market growth.

Opportunity: Emerging economies

Emerging markets such as India and China offer significant growth opportunities for diagnostics biomarkers. This is largely due to the growing patient population and the subsequent increase in diseases such as cardiovascular diseases and cancer in these countries. A research study published by the American Heart Association (AHA) found that with risk factors remaining constant, annual cardiovascular events in China were projected to increase by more than 50% from 2010 to 2030. According to The Lancet, cardiovascular diseases accounted for 28% of all deaths in India in 2016, and it is projected to increase to 36% by 2030. The increasing incidences & burden of cardiovascular diseases in emerging countries will drive the demand for early disease diagnostic procedures, which will offer various opportunities for players operating in the biomarker testing market.

Additionally, the leading players of this market are also adopting various strategies to expand their position and product offerings in these nations. For instance, in January 2020, Merck (Germany) opened a non-profit, high-tech skill development center in collaboration with the Council of Scientific and Industrial Research’s Institute of Microbial Technology (CSIR-IMTECH) in Chandigarh, India. The center is equipped with genome-editing, single-molecule biomarker detection, and other technologies to help local students build life science skills. Such strategies adopted by leading players are expected to drive the market for biomarker research in these counties.

Challenge: Technical issues related to sample collection & storage.

Many epidemiology studies use biomarkers to investigate different stages of diseases in humans. It requires careful handling and storage of precious biological samples to obtain a large amount of information from limited samples and minimize future research costs by using banked samples. Sample collection is thus one of the key issues faced by service providers, followed by access to these samples.

Similarly, stringent quality control is also required for these samples, and they need to be stored under the right conditions to avoid any loss. Different samples are required for risk detection, screening, diagnosis, and monitoring processes. The validity of results from biomarker studies using archived specimens depends on the integrity of specimens and how they were collected, processed, and stored. In addition to the consideration of maintenance of samples likely to yield valid results, specimen banks have to be structured so that all elements of patient rights, privacy, and confidentiality are maintained with informed consent that is thorough and addresses the potential use of samples. Furthermore, detailed tracking, specimen storage, and retrieval software are important for proper sample handling and management. Thus, both sample collection and storage may pose a challenge for the global market.

By product and service segment, the consumables segment accounted for the largest share of the biomarkers industry.

Based on product, the biomarkers market is segmented into consumables, services, and software. In 2022, the consumables segment accounted for the largest share of the global global market. The large share of this segment can primarily be attributed to the increasing use of kit-based products for biomarker testing and the repeated purchase of consumables.

By type, the safety biomarkers segment accounted for the largest share of the biomarkers industry.

On the basis of type, the biomarkers market is segmented into efficacy biomarkers, safety biomarkers, and validation biomarkers. In 2022, the safety biomarkers segment accounted for the largest share of the global market. Factors responsible for the large share of this segment are higher awareness of routine health checks in people, lower attrition rate for drugs and an increase in number of people with chronic diseases.

By disease indication, the cancer segment accounted for the largest share of the biomarkers industry.

On the basis of disease indication, the biomarkers market is segmented into cancer, infectious diseases, neurological disorders, immunological disorders, cardiovascular disorders, and other disease indications. In 2022, cancer segment accounted for the largest share of the global market. Factors responsible for the high growth of the segment includes early management and early detection by cancer biomarkers. In the future, the cancer biomarkers is expected to be further boosted by a strong pipeline of products from major manufacturers related to cancer.

By application, the diagnostics application segment accounted for the largest share of the biomarkers industry in 2022.

On the basis of application, the biomarkers market is segmented into diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other applications. In 2022, the diagnostics segment accounted for the largest share of the application segment in the market. Factor responsible for the growth in this segment include, the segment will expand as chronic diseases will become more prevalent, and targeted treatment and diagnosis demand will increase. The growing applications of biomarkers is also driving the growth of the diagnostics segment of the global market.

North America accounted for the largest share of the biomarkers industry.

North America accounted for the largest share of the biomarkers market. Factors responsible for the growth of the region includes increasing population suffering from chronic diseases in the region, increasing use of biomarkers in personalized medicine, various organic & inorganic growth strategies adopted by key players with established pharmaceutical companies in this region, increasing applications and advancements in biomarkers.

Biomarkers Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The biomarkers market is dominated by a few globally established players such as F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Enzo Biochem, Inc. (US), Charles River Laboratories International, Inc. (US), and Eurofins Scientific (Luxembourg).

Scope of the Biomarkers Industry

Report Metric

Details

Market Revenue in 2023

$59.1 billion

Projected Revenue by 2028

$104.0 billion

Revenue Rate

Poised to grow at a CAGR of 12.0%

Market Driver

Increasing prevalence of cancer worldwide

Market Opportunity

Emerging economies

The study categorizes the biomarkers market to forecast revenue and analyze trends in each of the following submarkets:

By Product

  • Consumables
  • Services
  • Software

By Type

  • Safety Biomarkers
  • Efficacy Biomarkers
  • Predictive Biomarkers
  • Surrogate Biomarkers
  • Pharmacodynamics Biomarkers
  • Prognostic Biomarkers
  • Validation Biomarkers

By Application

  • Diagnostics
  • Drug Discovery & Development
  • Personalized Medicine
  • Disease Risk Assessment
  • Other Applications

By Disease Indication

  • Cancer
  • Infectious Diseases
  • Immune Disorders
  • Neurological Disorders
  • Cardiovascular Disorders
  • Other Disease Indications

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • Italy
    • Spain
    • UK
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Rest of the World
    • Latin America
    • The Middle East and Africa

Recent Developments of Biomarkers Industry

  • In December 2022, F. Hoffmann-La Roche Ltd. (Switzerland) announced that Elecsys beta-amyloid (1-42) CSF II (Abeta42) and Elecsys phospho-Tau (181P) CSF (pTau181) assays had received U.S. Food and Drug Administration (FDA) 510(k) clearance. The Elecsys AD CSF Abeta42 and pTau181 assays (used as a pTau181/Abeta42 ratio) measure two biomarkers that are hallmarks of Alzheimer's pathology, beta-amyloid and tau proteins, in adults ages 55 and older being evaluated for the disease.
  • In September 2022, Enzo Biochem launched the AMPIVIEW Gene Expression Platform with products targeting the detection of HPV and SARS-CoV-2.
  • In April 2021, F. Hoffmann-La Roche Ltd. (Switzerland) launched two cardiac biomarker tests: high-sensitivity cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide (NT-proBNP). These gold standard biomarkers support cardiovascular disease management and can help clinicians diagnose heart attacks and manage heart failure better.
  • In May 2021, QIAGEN N.V. (Netherlands) launched the first FDA-approved tissue companion diagnostic, therascreen KRAS RGQ PCR Kit, to identify the KRAS G12C mutation in NSCLC tumors and expand precision medicine options in lung cancer.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 33)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
                    FIGURE 1 BIOMARKERS MARKET SEGMENTATION
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
           1.7.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 37)
    2.1 RESEARCH APPROACH 
          FIGURE 2 GLOBAL BIOMARKER DISCOVERY MARKET: RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
                    2.1.1.1 Secondary sources
           2.1.2 PRIMARY RESEARCH
                    2.1.2.1 Primary sources
                    2.1.2.2 Primary sources
                    2.1.2.3 Breakdown of primaries
                                FIGURE 3 GLOBAL MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 GLOBAL MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
          FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022
          FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF ALL BIOMARKER PRODUCTS IN THE MARKET
          FIGURE 7 KEY INDUSTRY INSIGHTS
          FIGURE 8 GLOBAL MARKET: CAGR PROJECTIONS, 2023–2028
          FIGURE 9 GLOBAL BIOMARKER DISCOVERY MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH LIMITATIONS 
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 RECESSION IMPACT 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
 
3 EXECUTIVE SUMMARY (Page No. - 51)
    FIGURE 11 BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE,  2023 VS. 2028 (USD MILLION)
    FIGURE 12 GLOBAL BIOMARKER DISCOVERY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 GLOBAL MARKET, BY DISEASE INDICATION,  2023 VS. 2028 (USD MILLION)
    FIGURE 14 GLOBAL BIOMARKER DISCOVERY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 15 GEOGRAPHICAL SNAPSHOT OF GLOBAL BIOMARKERS INDUSTRY
 
4 PREMIUM INSIGHTS (Page No. - 55)
    4.1 GLOBAL MARKET OVERVIEW 
          FIGURE 16 GROWING IMPORTANCE OF COMPANION DIAGNOSTICS EXPECTED TO DRIVE GLOBAL MARKET
    4.2 ASIA PACIFIC: GLOBAL BIOMARKER DISCOVERY MARKET, BY PRODUCT & SERVICE AND BY COUNTRY (2022) 
          FIGURE 17 CONSUMABLES ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022
    4.3 GLOBAL MARKET, BY REGION, 2022 
          FIGURE 18 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 58)
    5.1 MARKET DYNAMICS 
          FIGURE 19 BIOMARKERS MARKET SIZE: DRIVERS, RESTRAINTS, OPPORTUNITIES,  AND CHALLENGES
           5.1.1 MARKET DRIVERS
                    5.1.1.1 Growing importance of companion diagnostics
                    5.1.1.2 Increase in global prevalence of cancer
                                TABLE 2 NUMBER OF NEW CANCER CASES, BY TYPE, 2020–2040
                                TABLE 3 CANCER INCIDENCE, BY REGION (2040)
                    5.1.1.3 Increase in funds and grants for biomarker research
                    5.1.1.4 Continuous product innovations
                                TABLE 4 PRODUCT LAUNCHES, 2020−2022
           5.1.2 RESTRAINTS
                    5.1.2.1 High capital investments and lengthy timelines for biomarker development
                                TABLE 5 TIME FRAME FOR BIOMARKER DEVELOPMENT
           5.1.3 OPPORTUNITIES
                    5.1.3.1 Personalized medicine
                    5.1.3.2 Emerging economies
           5.1.4 CHALLENGES
                    5.1.4.1 Challenges associated with biomarker validation
                    5.1.4.2 Technical issues related to sample collection and storage
    5.2 REGULATORY ASSESSMENT 
           5.2.1 INTRODUCTION
           5.2.2 BIOMARKER QUALIFICATION IN US
           5.2.3 BIOMARKER QUALIFICATION IN EUROPE
    5.3 VALUE CHAIN ANALYSIS 
          FIGURE 20 GLOBAL MARKET: VALUE CHAIN ANALYSIS
    5.4 TECHNOLOGICAL ANALYSIS 
           5.4.1 IMMUNOASSAYS
                    5.4.1.1 Immunohistochemistry (IHC)
                    5.4.1.2 Flow cytometry
                    5.4.1.3 Flow cytometry ELISA
           5.4.2 NEXT-GENERATION SEQUENCING (NGS)
           5.4.3 POLYMERASE CHAIN REACTION (PCR)
           5.4.4 IN SITU HYBRIDIZATION
           5.4.5 MICROARRAYS
           5.4.6 MASS SPECTROMETRY
    5.5 PRICING ANALYSIS 
          TABLE 6 SELLING PRICE OF BIOMARKERS BY TOP PLAYERS
    5.6 PATENT ANALYSIS 
          FIGURE 21 PATENT APPLICATIONS FOR GLOBAL MARKET,  JANUARY 2012–DECEMBER 2022
    5.7 GLOBAL MARKET: SUPPLY CHAIN ANALYSIS 
          FIGURE 22 GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
           5.7.1 KEY INFLUENCERS
    5.8 ECOSYSTEM ANALYSIS 
          TABLE 7 GLOBAL BIOMARKERS INDUSTRY: SUPPLY CHAIN ECOSYSTEM
    5.9 KEY CONFERENCES AND EVENTS, 2023–2024 
          TABLE 8 GLOBAL MARKET: LIST OF CONFERENCES AND EVENTS
    5.10 PORTER’S FIVE FORCES ANALYSIS 
           5.10.1 IMPACT OF PORTER’S FIVE FORCES ON GLOBAL MARKET
           5.10.2 INTENSITY OF COMPETITIVE RIVALRY
           5.10.3 BARGAINING POWER OF SUPPLIERS
           5.10.4 BARGAINING POWER OF BUYERS
           5.10.5 THREAT OF SUBSTITUTES
           5.10.6 THREAT OF NEW ENTRANTS
    5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOMARKERS
           5.11.2 GLOBAL MARKET: BUYING CRITERIA
                     FIGURE 24 KEY BUYING CRITERIA FOR END USERS
    5.12 ECOSYSTEM ANALYSIS OF GLOBAL MARKET 
           FIGURE 25 GLOBAL MARKET: ECOSYSTEM ANALYSIS
           5.12.1 ROLE IN ECOSYSTEM
    5.13 REVENUE SHIFT FOR GLOBAL MARKET 
           FIGURE 26 GLOBAL BIOMARKERS INDUSTRY: REVENUE SHIFT
 
6 BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE (Page No. - 82)
    6.1 INTRODUCTION 
          TABLE 9 GLOBAL BIOMARKERS INDUSTRY, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
    6.2 CONSUMABLES 
           6.2.1 NEED FOR HIGH-FREQUENCY PURCHASE OF CONSUMABLES TO DRIVE MARKET GROWTH
                    TABLE 10 BIOMARKER CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 11 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 12 EUROPE: BIOMARKER CONSUMABLES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 13 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 14 ROW: BIOMARKER CONSUMABLES MARKET, BY REGION,  2021–2028 (USD MILLION)
    6.3 SERVICES 
           6.3.1 GRADUAL SHIFT FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING OF SERVICES TO SUPPORT MARKET GROWTH
                    TABLE 15 BIOMARKER SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 16 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 17 EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 18 ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 19 ROW: BIOMARKER SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
    6.4 SOFTWARE 
           6.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO SUPPORT MARKET GROWTH
                    TABLE 20 BIOMARKER SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 21 NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 22 EUROPE: BIOMARKER SOFTWARE MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 23 ASIA PACIFIC: BIOMARKER SOFTWARE MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 24 ROW: BIOMARKER SOFTWARE MARKET, BY REGION,  2021–2028 (USD MILLION)
 
7 BIOMARKERS MARKET SIZE, BY TYPE (Page No. - 90)
    7.1 INTRODUCTION 
          TABLE 25 GLOBAL BIOMARKERS INDUSTRY, BY TYPE, 2021–2028 (USD MILLION)
    7.2 EFFICACY BIOMARKERS 
          TABLE 26 EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 27 EFFICACY BIOMARKERS MARKET SHARE, BY REGION, 2021–2028 (USD MILLION)
          TABLE 28 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 29 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 30 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 31 ROW: MARKET, BY REGION,  2021–2028 (USD MILLION)
           7.2.1 PREDICTIVE BIOMARKERS
                    7.2.1.1 Wide applications of predictive biomarkers in personalized medicine and companion diagnostics to drive market
                                TABLE 32 PREDICTIVE BIOMARKERS MARKET SHARE, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 33 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 34 EUROPE: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 35 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 36 ROW: MARKET, BY REGION,  2021–2028 (USD MILLION)
           7.2.2 SURROGATE BIOMARKERS
                    7.2.2.1 Use of surrogate biomarkers helps accelerate drug development and shorten timelines for regulatory approval
                                TABLE 37 SURROGATE BIOMARKERS MARKET SHARE, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 38 NORTH AMERICA: BIOMARKER DISCOVERY MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 39 EUROPE: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 40 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 41 ROW: MARKET, BY REGION,  2021–2028 (USD MILLION)
           7.2.3 PHARMACODYNAMIC BIOMARKERS
                    7.2.3.1 Increasing utilization of pharmacodynamic biomarkers in selection and optimization of drug doses to boost market
                                TABLE 42 PHARMACODYNAMIC BIOMARKERS MARKET SHARE, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 43 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 44 EUROPE: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 45 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 46 ROW: MARKET, BY REGION,  2021–2028 (USD MILLION)
           7.2.4 PROGNOSTIC BIOMARKERS
                    7.2.4.1 Prognostic biomarkers help predict recurrence of diseases
                                TABLE 47 PROGNOSTIC BIOMARKERS MARKET SHARE, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 48 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 49 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 50 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 51 ROW: MARKET, BY REGION,  2021–2028 (USD MILLION)
    7.3 SAFETY BIOMARKERS 
           7.3.1 WIDE APPLICATIONS OF SAFETY BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT TO FUEL MARKET GROWTH
                    TABLE 52 SAFETY BIOMARKERS MARKET FORECAST, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 53 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 54 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 55 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 56 ROW: MARKET, BY REGION, 2021–2028 (USD MILLION)
    7.4 VALIDATION BIOMARKERS 
           7.4.1 VALIDATION BIOMARKERS ENABLE EVALUATION OF DIAGNOSTIC SYSTEMS
                    TABLE 57 VALIDATION BIOMARKERS MARKET FORECAST, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 58 NORTH AMERICA: BIOMARKER DISCOVERY MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 59 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 60 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 61 ROW: MARKET, BY REGION, 2021–2028 (USD MILLION)
 
8 BIOMARKERS MARKET FORECAST, BY DISEASE INDICATION (Page No. - 107)
    8.1 INTRODUCTION 
          TABLE 62 GLOBAL BIOMARKERS INDUSTRY, BY DISEASE INDICATION, 2021–2028 (USD MILLION)
    8.2 CANCER 
           8.2.1 INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH AND DIAGNOSIS TO DRIVE MARKET
                    TABLE 63 LIST OF FDA-APPROVED BIOMARKERS FOR DIFFERENT TYPES OF CANCER
                    TABLE 64 BIOMARKERS MARKET FORECAST FOR CANCER, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 65 NORTH AMERICA: MARKET FOR CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 66 EUROPE: MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 67 ASIA PACIFIC: MARKET FOR CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 68 ROW: MARKET FOR CANCER, BY REGION,  2021–2028 (USD MILLION)
    8.3 INFECTIOUS DISEASES 
           8.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE DEMAND FOR BIOMARKERS
                    TABLE 69 BIOMARKERS MARKET FORECAST FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 70 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 71 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 72 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 73 ROW: MARKET FOR INFECTIOUS DISEASES, BY REGION,  2021–2028 (USD MILLION)
    8.4 IMMUNOLOGICAL DISORDERS 
           8.4.1 INCREASING ADOPTION OF BIOMARKERS FOR VARIOUS IMMUNOLOGICAL DISORDERS TO DRIVE MARKET
                    TABLE 74 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS
                    TABLE 75 BIOMARKERS MARKET TRENDS FOR IMMUNOLOGICAL DISORDERS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 76 NORTH AMERICA: BIOMARKER DISCOVERY MARKET FOR IMMUNOLOGICAL DISORDERS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 77 EUROPE: MARKET FOR IMMUNOLOGICAL DISORDERS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 78 ASIA PACIFIC: MARKET FOR IMMUNOLOGICAL DISORDERS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 79 ROW: MARKET FOR IMMUNOLOGICAL DISORDERS,  BY REGION, 2021–2028 (USD MILLION)
    8.5 NEUROLOGICAL DISORDERS 
           8.5.1 IMMUNOASSAYS WIDELY USED IN DIAGNOSIS OF NEUROLOGICAL DISORDERS
                    TABLE 80 BIOMARKERS MARKET TRENDS FOR NEUROLOGICAL DISORDERS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 81 NORTH AMERICA: MARKET FOR NEUROLOGICAL DISORDERS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 82 EUROPE: MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 83 ASIA PACIFIC: MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 84 ROW: MARKET FOR NEUROLOGICAL DISORDERS, BY REGION,  2021–2028 (USD MILLION)
    8.6 CARDIOVASCULAR DISORDERS 
           8.6.1 GROWING PREVALENCE OF CVD TO INCREASE DEMAND FOR CARDIAC BIOMARKERS
                    TABLE 85 BIOMARKERS FOR CARDIOVASCULAR DISORDERS
                    TABLE 86 BIOMARKERS MARKET TRENDS FOR CARDIOVASCULAR DISORDERS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 87 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISORDERS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 88 EUROPE: MARKET FOR CARDIOVASCULAR DISORDERS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 89 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR DISORDERS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 90 ROW: MARKET FOR CARDIOVASCULAR DISORDERS,  BY REGION, 2021–2028 (USD MILLION)
    8.7 OTHER DISEASE INDICATIONS 
          TABLE 91 BIOMARKERS FOR RENAL DISORDERS
          TABLE 92 BIOMARKERS MARKET TRENDS FOR OTHER DISEASE INDICATIONS, BY REGION,  2021–2028 (USD MILLION)
          TABLE 93 NORTH AMERICA: BIOMARKER DISCOVERY MARKET FOR OTHER DISEASE INDICATIONS,  BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 94 EUROPE: MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 95 ASIA PACIFIC: MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 96 ROW: MARKET FOR OTHER DISEASE INDICATIONS, BY REGION,  2021–2028 (USD MILLION)
 
9 BIOMARKERS MARKET TRENDS, BY APPLICATION (Page No. - 124)
    9.1 INTRODUCTION 
          TABLE 97 GLOBAL BIOMARKERS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
    9.2 DIAGNOSTICS 
           9.2.1 INCREASING USE OF BIOMARKERS FOR DIAGNOSIS OF VARIOUS DISEASES TO DRIVE GROWTH
                    TABLE 98 BIOMARKERS MARKET OVERVIEW FOR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 99 NORTH AMERICA: MARKET FOR DIAGNOSTICS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 100 EUROPE: MARKET FOR DIAGNOSTICS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 101 ASIA PACIFIC: MARKET FOR DIAGNOSTICS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 102 ROW: MARKET FOR DIAGNOSTICS, BY REGION,  2021–2028 (USD MILLION)
    9.3 DRUG DISCOVERY & DEVELOPMENT 
           9.3.1 BIOMARKERS PLAY KEY ROLE AS BIOLOGICAL INDICATORS IN DEVELOPMENT OF NEW DRUGS
                    TABLE 103 BIOMARKERS MARKET OVERVIEW FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 104 NORTH AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 105 EUROPE: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 106 ASIA PACIFIC: MARKET FOR DRUG DISCOVERY & DEVELOPMENT,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 107 ROW: MARKET FOR DRUG DISCOVERY & DEVELOPMENT,  BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 PERSONALIZED MEDICINE 
           9.4.1 INCREASING APPLICATIONS OF BIOMARKERS IN PERSONALIZED MEDICINE TO DRIVE MARKET
                    TABLE 108 SELECTED PERSONALIZED MEDICINE DRUGS AND RELEVANT BIOMARKERS
                    TABLE 109 BIOMARKERS MARKET OVERVIEW FOR PERSONALIZED MEDICINE, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 110 NORTH AMERICA: BIOMARKER DISCOVERY MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 111 EUROPE: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 112 ASIA PACIFIC: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 113 ROW: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY,  2021–2028 (USD MILLION)
    9.5 DISEASE RISK ASSESSMENT 
           9.5.1 BIOMARKERS WIDELY USED FOR TOXICITY CHARACTERIZATION IN DISEASE DIAGNOSIS AND DRUG DEVELOPMENT PROCESSES
                    TABLE 114 BIOMARKERS MARKET OVERVIEW FOR DISEASE RISK ASSESSMENT, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 115 NORTH AMERICA: MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 116 EUROPE: MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 117 ASIA PACIFIC: MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 118 ROW: MARKET FOR DISEASE RISK ASSESSMENT, BY REGION,  2021–2028 (USD MILLION)
    9.6 OTHER APPLICATIONS 
          TABLE 119 BIOMARKERS MARKET OVERVIEW FOR OTHER APPLICATIONS, BY REGION,  2021–2028 (USD MILLION)
          TABLE 120 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 121 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 122 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 123 ROW: MARKET FOR OTHER APPLICATIONS, BY REGION,  2021–2028 (USD MILLION)
 
10 BIOMARKERS MARKET GROWTH, BY REGION (Page No. - 137)
     10.1 INTRODUCTION 
             TABLE 124 GLOBAL BIOMARKERS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 27 NORTH AMERICA: BIOMARKERS MARKET SNAPSHOT
             TABLE 125 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 126 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
             TABLE 127 NORTH AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 128 NORTH AMERICA: EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 129 NORTH AMERICA: BIOMARKERS MARKET SEGMENTS, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 130 NORTH AMERICA: BIOMARKER DISCOVERY MARKET, BY DISEASE INDICATION,  2021–2028 (USD MILLION)
             10.2.1 US
                        10.2.1.1 US expected to dominate biomarkers market growth in North America during forecast period
                                      TABLE 131 US: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 132 US: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 133 US: EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 134 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 135 US: BIOMARKERS MARKET SEGMENTS, BY DISEASE INDICATION, 2021–2028 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Increasing incidence of cancer to drive growth of biomarker research
                                      TABLE 136 CANADA: BIOMARKERS MARKET GROWTH, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 137 CANADA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 138 CANADA: EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 139 CANADA: BIOMARKERS MARKET PREDICTION, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 140 CANADA: BIOMARKER DISCOVERY MARKET, BY DISEASE INDICATION,  2021–2028 (USD MILLION)
             10.2.3 NORTH AMERICA: RECESSION IMPACT
     10.3 EUROPE 
             TABLE 141 EUROPE: BIOMARKERS MARKET GROWTH, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 142 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 143 EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 144 EUROPE: EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 145 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 146 EUROPE: MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Increase in government funding for biomarker research to drive market growth
                                      TABLE 147 GERMANY: BIOMARKERS MARKET GROWTH, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 148 GERMANY: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 149 GERMANY: EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 150 GERMANY: BIOMARKERS MARKET PREDICTION, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 151 GERMANY: BIOMARKER DISCOVERY MARKET, BY DISEASE INDICATION,  2021–2028 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers
                                      TABLE 152 UK: BIOMARKERS MARKET REPORT, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 153 UK: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 154 UK: EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 155 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 156 UK: MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Increasing government investments in genomics and proteomics research to drive market growth
                                      TABLE 157 FRANCE: BIOMARKERS MARKET REPORT, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 158 FRANCE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 159 FRANCE: EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 160 FRANCE: BIOMARKERS MARKET PREDICTION, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 161 FRANCE: BIOMARKER DISCOVERY MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Increasing life science R&D funding to drive market growth
                                      TABLE 162 ITALY: BIOMARKERS MARKET REPORT, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 163 ITALY: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 164 ITALY: EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 165 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 166 ITALY: MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Growing focus on cancer biomarkers to propel market growth
                                      TABLE 167 SPAIN: BIOMARKERS MARKET REPORT, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 168 SPAIN: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 169 SPAIN: EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 170 SPAIN: BIOMARKERS MARKET PREDICTION, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 171 SPAIN: BIOMARKER DISCOVERY MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION)
             10.3.6 REST OF EUROPE
                        TABLE 172 REST OF EUROPE: BIOMARKERS MARKET REPORT, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 173 REST OF EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 174 REST OF EUROPE: EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 175 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 176 REST OF EUROPE: MARKET, BY DISEASE INDICATION,  2021–2028 (USD MILLION)
             10.3.7 EUROPE: RECESSION IMPACT
     10.4 ASIA PACIFIC 
             TABLE 177 ASIA PACIFIC: BIOMARKERS MARKET ANALYSIS, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 178 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
             TABLE 179 ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 180 ASIA PACIFIC: EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 181 ASIA PACIFIC: BIOMARKERS MARKET PREDICTION, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 182 ASIA PACIFIC: BIOMARKER DISCOVERY MARKET, BY DISEASE INDICATION,  2021–2028 (USD MILLION)
             10.4.1 CHINA
                        10.4.1.1 Increasing burden of diseases and growing focus on development of novel drugs to drive demand for biomarkers
                                      TABLE 183 CHINA: BIOMARKERS MARKET ANALYSIS, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 184 CHINA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 185 CHINA: EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 186 CHINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 187 CHINA: MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Strategic collaborations with leading pharmaceutical companies to drive market
                                      TABLE 188 JAPAN: BIOMARKERS MARKET ANALYSIS, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 189 JAPAN: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 190 JAPAN: EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 191 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 192 JAPAN: BIOMARKER DISCOVERY MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Growing prevalence of target diseases expected to support global market
                                      TABLE 193 INDIA: BIOMARKERS MARKET ANALYSIS, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 194 INDIA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 195 INDIA: EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 196 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 197 INDIA: MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION)
             10.4.4 REST OF ASIA PACIFIC
                        TABLE 198 REST OF ASIA PACIFIC: BIOMARKERS MARKET ANALYSIS, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                        TABLE 199 REST OF ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 200 REST OF ASIA PACIFIC: EFFICACY BIOMARKER MARKET, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 201 REST OF ASIA PACIFIC: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                        TABLE 202 REST OF ASIA PACIFIC: BIOMARKER DISCOVERY MARKET, BY DISEASE INDICATION,  2021–2028 (USD MILLION)
             10.4.5 ASIA PACIFIC: RECESSION IMPACT
     10.5 REST OF THE WORLD 
             TABLE 203 ROW: BIOMARKERS MARKET SEGMENTS, BY REGION, 2021–2028 (USD MILLION)
             TABLE 204 ROW: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 205 ROW: MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 206 ROW: EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 207 ROW: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 208 ROW: MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION)
             10.5.1 LATIN AMERICA
                        10.5.1.1 Research funding and rising awareness of advanced sequencing technologies to drive market
                                      TABLE 209 LATIN AMERICA: BIOMARKERS MARKET SEGMENTS, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 210 LATIN AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 211 LATIN AMERICA: EFFICACY BIOMARKER MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 212 LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 213 LATIN AMERICA: BIOMARKER DISCOVERY MARKET, BY DISEASE INDICATION,  2021–2028 (USD MILLION)
             10.5.2 LATIN AMERICA: RECESSION IMPACT
             10.5.3 MIDDLE EAST & AFRICA
                        10.5.3.1 Increasing focus on proteomics and genomics research to support market growth
                                      TABLE 214 MIDDLE EAST & AFRICA: BIOMARKERS MARKET SEGMENTS, BY PRODUCT & SERVICE,  2021–2028 (USD MILLION)
                                      TABLE 215 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 216 MIDDLE EAST & AFRICA: EFFICACY BIOMARKER MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 217 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                      TABLE 218 MIDDLE EAST & AFRICA: MARKET, BY DISEASE INDICATION,  2021–2028 (USD MILLION)
             10.5.4 MIDDLE EAST & AFRICA: RECESSION IMPACT
 
11 COMPETITIVE LANDSCAPE (Page No. - 182)
     11.1 INTRODUCTION 
     11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 
             FIGURE28 BIOMARKERS MARKET: STRATEGIES ADOPTED
     11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE29 REVENUE ANALYSIS OF KEY COMPANIES OVER LAST THREE YEARS (2019–2022)
     11.4 MARKET SHARE ANALYSIS 
             FIGURE30 GLOBAL BIOMARKERS INDUSTRY: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
             TABLE 219 GLOBAL BIOMARKERS INDUSTRY: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION QUADRANT 
             FIGURE31 GLOBAL BIOMARKERS INDUSTRY: COMPANY EVALUATION MATRIX, 2022
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
     11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 
             11.6.1 PRODUCT & SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES)
                        TABLE 220 BIOMARKERS MARKET: PRODUCT & SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS
             11.6.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
                        TABLE 221 GLOBAL BIOMARKERS INDUSTRY: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
     11.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES 
             FIGURE32 GLOBAL BIOMARKERS INDUSTRY: COMPANY EVALUATION MATRIX FOR  START-UPS/SMES, 2022
             11.7.1 PROGRESSIVE COMPANIES
             11.7.2 STARTING BLOCKS
             11.7.3 RESPONSIVE COMPANIES
             11.7.4 DYNAMIC COMPANIES
     11.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 
             TABLE 222 GLOBAL BIOMARKERS INDUSTRY: DETAILED LIST OF KEY START-UP/SME PLAYERS
             TABLE 223 GLOBAL BIOMARKERS INDUSTRY: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
     11.9 COMPETITIVE SCENARIOS AND TRENDS 
             11.9.1 PRODUCT LAUNCHES
                        TABLE 224 GLOBAL BIOMARKERS INDUSTRY: PRODUCT LAUNCHES,  JANUARY 2020–DECEMBER 2022
             11.9.2 DEALS
                        TABLE 225 GLOBAL BIOMARKERS INDUSTRY: DEALS, JANUARY 2020–DECEMBER 2022
             11.9.3 EXPANSIONS
                        TABLE 226 BIOMARKERS MARKET: EXPANSIONS, JANUARY 2020–DECEMBER 2022
 
12 COMPANY PROFILES (Page No. - 196)
     12.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             12.1.1 MERCK KGAA
                        TABLE 227 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2021)
                        TABLE 228 OTHER DEVELOPMENTS
             12.1.2 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 229 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                        FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
             12.1.3 ABBOTT LABORATORIES
                        TABLE 230 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
             12.1.4 QIAGEN N.V.
                        TABLE 231 QIAGEN N.V.: BUSINESS OVERVIEW
                        FIGURE 36 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
             12.1.5 THERMO FISHER SCIENTIFIC INC.
                        TABLE 232 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021)
             12.1.6 PERKINELMER, INC.
                        TABLE 233 PERKINELMER, INC.: BUSINESS OVERVIEW
                        FIGURE 38 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
             12.1.7 BIO-RAD LABORATORIES, INC.
                        TABLE 234 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 39 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
             12.1.8 ENZO BIOCHEM, INC.
                        TABLE 235 ENZO BIOCHEM, INC.: BUSINESS OVERVIEW
                        FIGURE 40 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2022)
             12.1.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
                        TABLE 236 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
                        FIGURE 41 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.:  COMPANY SNAPSHOT (2021)
             12.1.10 EUROFINS SCIENTIFIC
                        TABLE 237 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 42 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)
             12.1.11 MESO SCALE DIAGNOSTICS, LLC
                        TABLE 238 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW
             12.1.12 STRESSMARQ BIOSCIENCES INC.
                        TABLE 239 STRESSMARQ BIOSCIENCES INC.: BUSINESS OVERVIEW
             12.1.13 AGILENT TECHNOLOGIES, INC.
                        TABLE 240 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                        FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)
             12.1.14 JOHNSON & JOHNSON
                        TABLE 241 JOHNSON & JOHNSON: BUSINESS OVERVIEW
                        FIGURE 44 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2021)
             12.1.15 DIAMETRA
                        TABLE 242 DIAMETRA: BUSINESS OVERVIEW
             12.1.16 SIGNOSIS, INC.
                        TABLE 243 SIGNOSIS, INC.: BUSINESS OVERVIEW
     12.2 OTHER PLAYERS 
             12.2.1 SINGULEX, INC.
                        TABLE 244 SINGULEX, INC.: BUSINESS OVERVIEW
             12.2.2 BIOMÉRIEUX SA
                        TABLE 245 BIOMÉRIEUX SA: BUSINESS OVERVIEW
             12.2.3 CISBIO BIOASSAYS
                        TABLE 246 CISBIO BIOASSAYS: BUSINESS OVERVIEW
             12.2.4 EKF DIAGNOSTICS HOLDINGS, PLC
                        TABLE 247 EKF DIAGNOSTICS HOLDINGS, PLC: BUSINESS OVERVIEW
             12.2.5 MICROCONSTANTS, INC.
                        TABLE 248 MICROCONSTANTS, INC.: BUSINESS OVERVIEW
             12.2.6 NORTHEAST BIOANALYTICAL LABORATORIES LLC.
                        TABLE 249 NORTHEAST BIOANALYTICAL LABORATORIES LLC.: BUSINESS OVERVIEW
             12.2.7 JSR LIFE SCIENCES, LLC
                        TABLE 250 JSR LIFE SCIENCES, LLC: BUSINESS OVERVIEW
             12.2.8 BIOAGILYTIX LABS
                        TABLE 251 BIOAGILYTIX LABS: BUSINESS OVERVIEW
             12.2.9 CELERION
                        TABLE 252 CELERION: BUSINESS OVERVIEW
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 249)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global biomarkers market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and assess market growth prospects. The global size of the biomarkers market (estimated through various secondary research approaches) was then triangulated with primary research inputs to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from organizations such as the World Bank, GLOBOCAN, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Cancer Institute, Food and Drug Administration (FDA), European Medicines Agency, National Comprehensive Cancer Network (NCCN), The European Association for Cancer Research (EACR), Australian Cancer Research Foundation (ACRF), and National Institutes of Health (NIH).

Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global biomarkers market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global biomarkers market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand-side (such as personnel from pharmaceutical & biotechnology companies, academia, research, and CROs) and supply-side (such as C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering biomarkers) across five major regions—North America, Europe, the Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Approximately 70% and 30% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

Biomarkers Market Size

To know about the assumptions considered for the study, download the pdf brochure

Data Triangulation

After arriving at the overall size of the biomarkers market through the methodology mentioned above, this market was split into several segments and subsegments. Market breakdown procedures were employed, wherever applicable, to arrive at the exact market value for the key segments and subsegments. The extrapolated market data was triangulated by studying various macroindicators and regional trends from both demand and supply-side participants.

Report Objectives

  • To define, describe, and forecast the global biomarkers market on the basis of product & service, type, application, disease indication, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets and subsegments with respect to individual growth trends, future prospects, and contributions to the overall biomarkers market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To profile the key players in the global biomarkers market and comprehensively analyze their core competencies and market rankings
  • To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)
  • To track and analyze competitive developments such as acquisitions, new product developments & approvals, agreements, partnerships and collaborations in the biomarkers market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographic Analysis

  • Further breakdown of the European biomarkers market into RoE countries
  • Further breakdown of the Asia Pacific biomarkers market into RoAPAC countries

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 2120
Published ON
Feb, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Biomarkers Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback